Physician profile
David P Kelsen
NPI 1275504060
$119,068.39
in general payments reported to CMS, 2019-2025
12 companies · $8,575 in 2025
The $8,575 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,304 · 2020: $16K · 2021: $31K · 2022: $6,750 · 2023: $19K · 2024: $29K · 2025: $8,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Travel and Lodging: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,594.25 |
| Travel and Lodging | $108.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25,385.45 | 2020-2024 | Keytruda |
| Janssen Research & Development, LLC | $14,875.00 | 2024-2025 | Darzalex, Carvykti |
| Glaxosmithkline, LLC. | $13,950.00 | 2020-2023 | Jemperli |
| E.R. Squibb & Sons, L.L.C. | $12,464.29 | 2021-2024 | |
| Daiichi Sankyo INC. | $9,303.65 | 2019 | |
| Incyte Corporation | $8,540.00 | 2021 | |
| Blueprint Medicines Corporation | $8,400.00 | 2021 | |
| Tg Therapeutics, INC. | $6,750.00 | 2022 | |
| Acrotech Biopharma INC. | $6,300.00 | 2023 | Beleodaq |
| Pharmacyclics LLC, An Abbvie Company | $6,050.00 | 2023 | Imbruvica |
| Abbvie INC. | $6,050.00 | 2024 | |
| Celularity INC. | $1,000.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kelsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.